Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 1/20 | 0.80 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.78 |
| ▸ | MEN1 | O00255 | 3/20 | 0.78 |
| ▸ | POLB | P06746 | 2/20 | 0.78 |
| ▸ | APEX1 | P27695 | 1/20 | 0.78 |
| ▸ | RECQL | P46063 | 1/20 | 0.78 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.78 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.78 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.78 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.78 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.78 |
| ▸ | CYP19A1 | P11511 | 5/20 | 0.72 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.72 |
| ▸ | ESR1 | P03372 | 3/20 | 0.72 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.72 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.72 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.72 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.72 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.72 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL476289 | 1.00 | PLK1 (0.80) | PLK1KMT2AMEN1POLBAPEX1 | |
| SCHEMBL30064298 | 1.00 | PLK1 (0.80) | PLK1KMT2AMEN1POLBAPEX1 | |
| Succedaneaflavanone SCHEMBL615879 | 0.91 | KMT2A (0.78) | PLK1KMT2AMEN1POLBAPEX1 | |
| SCHEMBL31173123 | 0.89 | PLK1 (1.00) | PLK1KMT2AMEN1POLBAPEX1 | |
| SCHEMBL12068882 | 0.89 | PLK1 (1.00) | PLK1KMT2AMEN1POLBAPEX1 | |
| SCHEMBL24406183 | 0.88 | KMT2A (1.00) | PLK1KMT2AMEN1POLBAPEX1 | |
| SCHEMBL29099768 | 0.88 | KMT2A (1.00) | PLK1KMT2AMEN1POLBAPEX1 | |
| SCHEMBL29906199 | 0.88 | KMT2A (1.00) | PLK1KMT2AMEN1POLBAPEX1 | |
| SCHEMBL12067051 | 0.86 | PLK1 (0.76) | PLK1KMT2AMEN1POLBAPEX1 | |
| SCHEMBL27830641 | 0.85 | CYP1A1 (0.74) | PLK1KMT2AMEN1POLBAPEX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113791154-B | Method for identifying chemical components in Xuebijing injection | 天津中医药大学 | 2023-06-23 | — | — | CN | disclosed |
| EP-2411031-A2 | Methods and compositions for the treatment of cancer | Bionovo Inc. (US) | 2012-02-01 | — | — | EP | disclosed |
| EP-2340027-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | Bionovo Inc. (US) | 2011-07-06 | — | — | EP | disclosed |
| WO-2010110993-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | BIONOVO, INC. (US) | 2010-09-30 | — | — | WO | disclosed |
| US-20100069481-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | BIONOVO, INC. (US) | 2010-03-18 | — | — | US | disclosed |
| US-20100069480-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | Bionovo, Inc. A Delaware Corporation (US) | 2010-03-18 | — | — | US | disclosed |
| WO-2010028187-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | BIONOVO, INC. (US) | 2010-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069480-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | BAX, BCL2L11, BCL2 | PLK1 130/4885KMT2A 2214/4885MEN1 4348/4885 |
| US-20100069481-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | BAX, BCL2L11, BCL2 | PLK1 130/4885KMT2A 2214/4885MEN1 4348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.